Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into phase 2. The Waltham, Massachusetts-based company already unveiled ...

Several years ago, my dad was diagnosed with pulmonary fibrosis. The news was a shock. At 84 years old, Daddy had been dedicated to his physical health for decades. He played tennis twice a week, ate ...

Sophie Pierce will be the first person with cystic fibrosis to do just that, travelling from Lanzarote to Antigua. A historic achievement when you consider what she's been through and when ...

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it. And, as University of South Florida pulmonologist Dr.

Department of Radiology, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210008, China ...

SNT-5382 is under development for the treatment of idiopathic pulmonary fibrosis, chronic kidney disease, non-alcoholic steatohepatitis. The drug candidate is administered orally. It targets lysyl ...

has been tested and shown to reduce RV fibrosis without modifying RV afterload. Considering the strong correlation between the extent of collagen cross-linking with impairment of cardiac function and ...

Background: Lysyl oxidases (LOXs), including LOX, LOXL1, LOXL2, LOXL3, and LOXL4, catalyze the formation of a cross-link between elastin (ELN) and collagen. Multiple LOX mutations have been shown to ...